Economic evaluation for the United States (US) of gemcitabine (GEM), nab-paclitaxel plus gemcitabine (NAB-P plus GEM), and FOLFIRINOX as first-line treatment for metastatic pancreatic cancer (MPC)

被引：0
|
作者：
Gharaibeh, Mahdi
McBride, Ali
Bootman, J. Lyle
Cranmer, Lee D.
Abraham, Ivo
机构：
[1] Ctr Hlth Outcomes & PharmacoEcon Res, Tucson, AZ USA
[2] Univ Arizona, Ctr Canc, Tucson, AZ USA
[3] Univ Arizona, Ctr Hlth Outcomes & PharmacoEcon Res, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.6605
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6605
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of first-line gemcitabine plus nab-paclitaxel for elderly metastatic pancreatic cancer patients
    Pecora, I.
    Vivaldi, C.
    Rovesti, G.
    Catanese, S.
    Salani, F.
    Gardini, A. Casadei
    Massa, V.
    Bernardini, L.
    Riggi, M.
    Andrikou, K.
    Rapposelli, I.
    Formica, V.
    Cesario, S.
    Caccese, M.
    Lencioni, M.
    Vasile, E.
    Falcone, A.
    Fornaro, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S151 - S151
  • [42] Phase III study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with metastatic pancreatic adenocarcinoma (mPC): Subgroup analysis of Canadian pts from the MPACT trial
    Tehfe, Mustapha Ali
    Dowden, Scot D.
    Kennecke, Hagen F.
    El-Maraghi, Robert Hassan
    Lesperance, Bernard
    Couture, Felix
    Letourneau, Richard
    Penenberg, Darryl Neil
    Romano, Alfredo
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [43] Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer
    Gharaibeh, M.
    McBride, A.
    Bootman, J. L.
    Abraham, I.
    BRITISH JOURNAL OF CANCER, 2015, 112 (08) : 1301 - 1305
  • [44] tnAcity: A phase II/III trial of nab-paclitaxel (nab-P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple-negative metastatic breast cancer (TNMBC)
    Yardley, Denise A.
    Coleman, Robert E.
    Conte, Pierfranco
    O'Shaughnessy, Joyce
    Cortes, Javier
    Glueck, Stefan
    Brufsky, Adam
    Nabholtz, Jean-Marc A.
    Li, Li
    Miller, JulieAnn
    Barton, Debora
    Harbeck, Nadia
    CANCER RESEARCH, 2015, 75
  • [45] Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer
    M Gharaibeh
    A McBride
    J L Bootman
    I Abraham
    British Journal of Cancer, 2015, 112 : 1301 - 1305
  • [46] The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence
    Prejac, Juraj
    Hamzic, Dora Tomek
    Librenjak, Niksa
    Gorsic, Irma
    Kekez, Domina
    Plestina, Stjepko
    MEDICINE, 2022, 101 (39) : E30566
  • [47] Tumor reduction in pancreatic versus metastatic sites in a randomized phase III study (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.
    Kunzmann, Volker
    Ramanathan, Ramesh K.
    Goldstein, David
    Penenberg, Darryl Neil
    Ferrara, Stefano
    Lu, Brian
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [48] Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival
    Tempero, M.
    O'Reilly, E.
    Van Cutsem, E.
    Berlin, J.
    Philip, P.
    Goldstein, D.
    Tabernero, J.
    Borad, M.
    Bachet, J.
    Parner, V.
    Tebbutt, N.
    Chua, Y.
    Corrie, P.
    Harris, M.
    Taieb, J.
    Burge, M.
    Kunzmann, V.
    Zhang, G.
    McGovern, D.
    Marks, H.
    Biankin, A.
    Reni, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S226 - S226
  • [49] ECONOMIC EVALUATION OF NAB-PACLITAXEL PLUS GEMCITABINE VERSUS GEMCITABINE ALONE FOR THE MANAGEMENT OF METASTATIC PANCREATIC CANCER IN GREECE
    Fragoulakis, V
    Papakostas, P.
    Pentheroudakis, G.
    Dervenis, C.
    Maniadakis, N.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
  • [50] Real world hospital costs associated with nab-paclitaxel plus gemcitabine (nab-P plus G) and FOLFIRINOX (FFX) as first line (1 L) treatment (tx) for metastatic pancreatic adenocarcinoma (MPAC).
    Kim, George P.
    Parisi, Monika
    Patel, Manish
    Belk, Kathy
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345